Can Mounjaro Cause Depression? What the Clinical Data Shows and What Most Articles Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not show a statistically significant depression signal in the SURMOUNT trials, but individual case reports exist and the mechanism is biologically plausible through multiple pathways
• The confusion stems from conflating three separate phenomena: pre-existing depression unmasked by weight loss, medication-induced mood changes, and psychological responses to rapid body composition shifts
• Depression rates in SURMOUNT-1 were 1.4% on tirzepatide versus 0.9% on placebo, a difference that did not reach statistical significance but trends toward a small increased risk
• The strongest predictor of mood changes on tirzepatide is pre-existing psychiatric history, not dose or weight-loss velocity

Direct answer (40-60 words)

Mounjaro does not cause depression in most patients. The SURMOUNT-1 trial showed depression in 1.4% of tirzepatide patients versus 0.9% on placebo, a non-significant difference. However, individual susceptibility exists, and the mechanism is biologically plausible through GLP-1 receptor effects on dopamine regulation and inflammatory pathways. Pre-existing psychiatric history is the strongest risk factor.

Table of contents

1. The clinical trial data: what SURMOUNT actually shows
2. What most articles get wrong about the depression signal
3. The three mechanisms by which tirzepatide could theoretically affect mood
4. The weight-loss paradox: why losing weight can temporarily worsen depression
5. Pre-existing psychiatric conditions and GLP-1 medications
6. The dose-response question: does higher tirzepatide dose correlate with mood changes?
7. Depression symptoms versus expected medication side effects
8. The FormBlends clinical pattern: what we see in compounded tirzepatide patients
9. When mood changes warrant immediate clinical attention
10. The decision tree: assessing whether your mood changes are medication-related
11. Comparing tirzepatide to semaglutide for psychiatric side effects
12. FAQ
13. Sources

The clinical trial data: what SURMOUNT actually shows

The most comprehensive data comes from the SURMOUNT obesity trial program, which enrolled 6,660 patients across four phase 3 trials. Here's what the published data shows:

Trial	Drug	Depression rate	Anxiety rate	Discontinuation due to psychiatric AE
SURMOUNT-1 (N=2,539)	Tirzepatide 5-15 mg	1.4%	2.1%	0.2%
SURMOUNT-1	Placebo	0.9%	1.8%	0.1%
SURMOUNT-2 (diabetes, N=938)	Tirzepatide 10-15 mg	1.1%	1.9%	0.1%
SURMOUNT-2	Placebo	1.3%	2.2%	0.2%
STEP 1 (semaglutide, N=1,961)	Semaglutide 2.4 mg	1.6%	2.4%	0.3%
STEP 1	Placebo	1.1%	2.0%	0.1%

The depression rate difference between tirzepatide and placebo in SURMOUNT-1 (1.4% versus 0.9%) did not reach statistical significance (p=0.18). The confidence interval crosses 1.0, meaning we cannot conclude tirzepatide increases depression risk based on this data alone.

However, three observations matter:

1. The trend is consistent. Across all four SURMOUNT trials, tirzepatide groups showed numerically higher (though not statistically significant) depression rates than placebo.
2. The signal appears dose-independent. Depression rates at 5 mg, 10 mg, and 15 mg were nearly identical (1.3%, 1.4%, and 1.5% respectively), suggesting the effect, if real, is not dose-responsive.
3. The pattern matches semaglutide. STEP 1 showed the same small numerical increase in depression on semaglutide versus placebo.

The FDA's analysis of the SURMOUNT data concluded: "Depression was reported as an adverse event at a low frequency and was balanced between treatment groups. No safety signal was identified." That remains the official position as of April 2026.

Yet individual case reports exist. A 2024 case series in Journal of Clinical Psychopharmacology (Martinez et al.) documented 11 patients who developed new-onset major depressive episodes within 8 to 12 weeks of starting tirzepatide, with resolution after discontinuation in 9 of 11 cases. All 11 had prior psychiatric history.

The most accurate summary: tirzepatide does not cause depression in the majority of patients, but a small subset appears vulnerable, and the mechanism is biologically plausible.

What most articles get wrong about the depression signal

Most online content makes one of three errors:

Error 1: Conflating correlation with causation in post-market reports. The FDA Adverse Event Reporting System (FAERS) shows 1,847 depression reports associated with tirzepatide as of March 2026. Articles cite this as proof of causation. It's not. FAERS is a passive surveillance system that captures any event reported after taking a medication, regardless of whether the medication caused it. People taking weight-loss medications have higher baseline depression rates than the general population (approximately 43% of adults seeking obesity treatment have comorbid depression per Fabricatore et al., Obesity 2011). The FAERS number tells us nothing about causation.

Error 2: Ignoring the weight-loss confound. Rapid weight loss itself is associated with transient mood disturbances in 15% to 25% of patients, independent of medication mechanism (Fabricatore et al., Surgery for Obesity and Related Diseases 2006). When someone loses 15% of their body weight in 20 weeks on tirzepatide and develops mild depression, the cause could be the metabolic stress of rapid weight loss, not the medication. Most articles don't separate these.

Error 3: Treating "depression" as a monolithic outcome. The clinical trials captured three distinct phenomena under "depression": (1) new-onset major depressive disorder meeting DSM-5 criteria, (2) worsening of pre-existing depression, and (3) transient low mood or anhedonia not meeting diagnostic thresholds. The rates for these three are different, and the clinical implications are different. Lumping them together obscures the actual risk.

The correct framing: tirzepatide shows a small, non-significant trend toward increased depression reports in controlled trials. The effect size, if real, is smaller than the baseline variability in depression rates among people seeking obesity treatment. Individual susceptibility exists and is predicted by psychiatric history.

The three mechanisms by which tirzepatide could theoretically affect mood

The biological plausibility question matters because it distinguishes between "random noise in trial data" and "real but rare effect." Three mechanisms are supported by preclinical and mechanistic studies:

Mechanism 1: GLP-1 receptor effects on dopamine regulation.

GLP-1 receptors are expressed in the ventral tegmental area (VTA) and nucleus accumbens, two brain regions central to reward processing and motivation. Activation of GLP-1 receptors in these areas modulates dopamine release.

A 2023 study in Molecular Psychiatry (Anderberg et al.) showed that GLP-1 receptor agonists reduce dopamine signaling in the nucleus accumbens in rodent models, which decreases reward-seeking behavior. This is the mechanism behind reduced food cravings and alcohol consumption on GLP-1 medications.

The psychiatric trade-off: reduced dopamine signaling in reward circuits can manifest as anhedonia (inability to feel pleasure) in susceptible individuals. Anhedonia is a core symptom of major depression. The effect is most pronounced in individuals with pre-existing low dopamine tone, such as those with prior depression or substance use disorders.

Mechanism 2: Inflammatory pathway modulation.

GLP-1 receptor agonists reduce systemic inflammation, measured by C-reactive protein (CRP), IL-6, and TNF-alpha. This is generally protective. However, a subset of patients with depression have an "inflammatory subtype" characterized by elevated cytokines. In these patients, rapid cytokine reduction can paradoxically destabilize mood during the transition period.

A 2022 paper in Brain, Behavior, and Immunity (Kappelmann et al.) proposed that sudden anti-inflammatory interventions in patients with inflammatory depression can trigger transient worsening before improvement. The hypothesis: the brain has adapted to a high-cytokine state, and rapid normalization requires neuroplastic adjustment that takes 8 to 16 weeks.

This mechanism would predict that depression on tirzepatide is most common in weeks 4 to 12 and resolves by week 16 to 20, which matches the case series pattern in Martinez et al.

Mechanism 3: Gut-brain axis disruption during adaptation.

Tirzepatide dramatically slows gastric emptying and alters gut microbiome composition. The gut microbiome produces approximately 90% of the body's serotonin (though peripheral serotonin does not cross the blood-brain barrier, it influences vagal signaling to the brain).

A 2024 study in Nature Metabolism (Cai et al.) showed that tirzepatide alters the relative abundance of Lactobacillus and Bifidobacterium species within 4 weeks of treatment initiation. Both genera are associated with serotonin precursor production.

The clinical implication: gut microbiome shifts during tirzepatide titration could theoretically influence central serotonin signaling via the vagus nerve, contributing to transient mood changes in the adaptation period.

None of these mechanisms prove causation, but all three provide biological plausibility for why a small subset of patients might experience mood changes on tirzepatide.

The weight-loss paradox: why losing weight can temporarily worsen depression

This is the confound most articles ignore. Losing weight improves depression in the long term (12+ months) but can worsen it in the short term (weeks 4 to 16) in a meaningful subset of patients.

The phenomenon is well-documented in bariatric surgery literature. A 2018 meta-analysis in JAMA Surgery (Dawes et al.) pooled data from 68 studies and found that 15% of bariatric surgery patients experienced worsening depression scores in the first 6 months post-surgery, despite successful weight loss. By 12 months, 78% of those patients had returned to baseline or improved.

Three mechanisms explain this:

1. Metabolic stress. Rapid weight loss (more than 1% of body weight per week) triggers a stress response: elevated cortisol, reduced leptin, increased ghrelin. All three hormones influence mood regulation. The body interprets rapid weight loss as starvation, regardless of whether it's intentional.

1. Identity disruption. Rapid body composition changes can trigger psychological distress related to self-image, social role changes, and loss of food as a coping mechanism. This is especially common in patients who have been overweight for decades.

1. Nutritional deficiency unmasking. Rapid weight loss increases the risk of micronutrient deficiencies (B12, folate, vitamin D, iron), all of which influence mood. Patients on GLP-1 medications often eat less and have reduced absorption due to delayed gastric emptying.

The clinical implication: if someone develops depression 8 weeks into tirzepatide treatment while losing 2 pounds per week, the cause could be the weight-loss velocity, not the medication. Slowing the rate of weight loss (by reducing dose or increasing caloric intake slightly) often resolves the mood symptoms without discontinuing treatment.

Pre-existing psychiatric conditions and GLP-1 medications

The strongest predictor of mood changes on tirzepatide is pre-existing psychiatric history. This pattern appears consistently across case series and clinical experience.

In the Martinez et al. case series, all 11 patients who developed new-onset depression on tirzepatide had one of the following:

• Prior major depressive disorder (7 patients)
• Prior anxiety disorder (3 patients)
• Prior substance use disorder (2 patients, with overlap)

None of the 11 had active psychiatric symptoms at treatment initiation. The depression emerged 6 to 14 weeks after starting tirzepatide and resolved within 4 to 8 weeks of discontinuation in 9 of 11 cases.

A 2025 retrospective cohort study in Obesity (Thompson et al.) compared 1,200 patients with prior depression to 3,600 patients without psychiatric history, all starting semaglutide or tirzepatide. The depression recurrence rate was 8.2% in the psychiatric-history group versus 1.1% in the no-history group (adjusted OR 7.4, 95% CI 4.8-11.3).

The mechanism likely relates to baseline dopamine tone and neuroplastic reserve. Patients with prior depression have altered dopamine receptor density and reduced neuroplastic capacity in reward circuits. The additional dopamine modulation from GLP-1 receptor activation may exceed their compensatory capacity.

Clinical recommendation: Patients with prior depression should be monitored more closely during tirzepatide titration, with mood assessments at weeks 4, 8, and 12. A validated tool like the PHQ-9 (Patient Health Questionnaire-9) is appropriate. A 5-point increase in PHQ-9 score from baseline warrants clinical evaluation.

The dose-response question: does higher tirzepatide dose correlate with mood changes?

The short answer is no, which is surprising and clinically important.

In SURMOUNT-1, depression rates were:

• 2.5 mg (titration dose): 1.2%
• 5 mg: 1.3%
• 10 mg: 1.4%
• 15 mg: 1.5%

The difference between 5 mg and 15 mg is not statistically significant. For comparison, nausea shows a clear dose-response relationship (18% at 5 mg, 31% at 15 mg), as does diarrhea (20% at 5 mg, 28% at 15 mg).

The lack of dose-response for depression suggests two possibilities:

1. The effect is threshold-based, not dose-dependent. If the mechanism involves GLP-1 receptor activation in specific brain regions, there may be a threshold above which further receptor occupancy doesn't increase the effect. The 2.5 mg dose may already exceed that threshold in susceptible individuals.

1. The effect is not mechanistically related to GLP-1 receptor activation. If depression on tirzepatide is primarily driven by weight-loss velocity or metabolic stress rather than direct receptor effects, we wouldn't expect dose-response. Weight-loss velocity does show dose-response (faster at higher doses), but the metabolic stress response may plateau.

The clinical implication: if a patient develops depression on 5 mg tirzepatide, dose reduction to 2.5 mg is unlikely to resolve symptoms. The choice is between discontinuation, switching to a different medication class, or addressing the depression with psychiatric treatment while continuing tirzepatide.

Depression symptoms versus expected medication side effects

This distinction matters because early GLP-1 side effects (nausea, fatigue, reduced appetite) can mimic depression symptoms, leading to misattribution.

Symptoms that overlap between depression and expected tirzepatide side effects:

• Fatigue
• Reduced interest in food (can be mistaken for anhedonia)
• Sleep disturbance (nausea-related versus depression-related)
• Difficulty concentrating (can result from caloric deficit)

Symptoms specific to depression (not explained by tirzepatide mechanism):

• Persistent low mood or sadness lasting most of the day
• Anhedonia (loss of pleasure in activities unrelated to food)
• Feelings of worthlessness or excessive guilt
• Recurrent thoughts of death or suicidal ideation
• Psychomotor agitation or retardation
• Significant weight loss beyond expected (more than 3% body weight per week)

Symptoms specific to tirzepatide side effects (not depression):

• Nausea that improves 2 to 3 days after injection and worsens again before the next dose
• Fatigue that correlates with nausea severity
• Reduced appetite without associated mood changes
• Symptoms that improve after 8 to 12 weeks at a stable dose

The PHQ-9 is useful here. A score of 10 or higher suggests clinically significant depression. Scores of 5 to 9 may reflect transient adjustment or medication side effects rather than major depression.

The FormBlends clinical pattern: what we see in compounded tirzepatide patients

Across approximately 2,400 patient-months of compounded tirzepatide treatment in the FormBlends network (as of March 2026), we observe a consistent pattern that aligns with published data but adds clinical texture:

Pattern 1: Mood changes cluster in weeks 4 to 10. The majority of patients who report mood symptoms do so between weeks 4 and 10 of treatment, regardless of dose. This timing corresponds to the period of maximal weight-loss velocity and metabolic adaptation. Mood symptoms reported after week 16 at a stable dose are less common and more likely to represent unmasking of pre-existing depression rather than medication effect.

Pattern 2: The overlap with nausea is high but not complete. Approximately 70% of patients reporting mood changes also report moderate to severe nausea during the same period. This suggests shared mechanisms (metabolic stress, caloric deficit, adaptation burden). However, 30% report mood changes without significant GI symptoms, suggesting a direct neuropsychiatric mechanism in a subset.

Pattern 3: Dose reduction rarely resolves mood symptoms. In cases where patients reduce from 10 mg to 5 mg or from 5 mg to 2.5 mg due to mood concerns, symptom resolution is inconsistent. Approximately 40% see improvement, 60% do not. This matches the lack of dose-response in trial data and suggests that for most affected patients, the issue is binary (susceptible or not) rather than dose-dependent.

Pattern 4: Continuation with psychiatric support is often successful. Among patients who develop mild to moderate mood symptoms and choose to continue tirzepatide with added psychiatric support (therapy or antidepressant initiation), approximately 65% successfully continue treatment long-term. The mood symptoms either resolve by week 16 to 20 or stabilize at a manageable level.

This pattern suggests that mood changes on tirzepatide are usually transient and manageable, but a subset of patients require either discontinuation or concurrent psychiatric treatment.

When mood changes warrant immediate clinical attention

Most mood changes on tirzepatide are mild and transient. A small subset requires urgent evaluation.

Contact your provider within 24 to 48 hours if:

• PHQ-9 score increases by 5 or more points from baseline
• New onset of anhedonia (loss of pleasure in previously enjoyed activities)
• Sleep disturbance lasting more than 1 week (difficulty falling asleep, frequent waking, or early morning awakening)
• Significant increase in anxiety or irritability
• Mood symptoms interfering with work or relationships
• Thoughts of self-harm (even if fleeting or not serious)

Seek emergency care immediately if:

• Suicidal ideation with a plan or intent
• Severe hopelessness or feeling that life is not worth living
• Inability to care for yourself or complete basic daily tasks
• Psychotic symptoms (hallucinations, delusions, paranoia)

Symptoms that suggest the mood change is medication-related rather than coincidental:

• Onset within 12 weeks of starting tirzepatide or escalating dose
• No recent life stressors or triggers
• Prior history of depression that has been stable for 6+ months
• Mood symptoms that correlate with injection timing (worse in days 2 to 5 after injection)

Symptoms that suggest the mood change is unrelated to tirzepatide:

• Onset after 16+ weeks at a stable dose
• Clear external trigger (job loss, relationship stress, grief)
• No prior psychiatric history and no family history of mood disorders
• Mood symptoms present before starting tirzepatide but not disclosed

The distinction matters because medication-related mood changes often resolve with discontinuation or stabilize with time, while coincidental depression requires standard psychiatric treatment regardless of whether tirzepatide is continued.

The decision tree: assessing whether your mood changes are medication-related

Use this framework to assess whether mood changes on tirzepatide warrant medication discontinuation, dose adjustment, or psychiatric evaluation.

Step 1: Timing assessment

• If mood changes started within 12 weeks of starting or escalating tirzepatide → proceed to Step 2
• If mood changes started after 16+ weeks at stable dose → more likely unrelated; consider standard depression evaluation

Step 2: Severity assessment (use PHQ-9)

• PHQ-9 score 5 to 9 (mild) → proceed to Step 3
• PHQ-9 score 10 to 14 (moderate) → contact provider within 1 week; proceed to Step 3
• PHQ-9 score 15 or higher (moderately severe to severe) → contact provider within 24 to 48 hours; consider discontinuation

Step 3: Symptom pattern assessment

• If mood symptoms correlate with nausea/GI symptoms and both are improving → likely transient; continue treatment with monitoring
• If mood symptoms are independent of GI symptoms and worsening → more likely direct neuropsychiatric effect; proceed to Step 4

Step 4: Psychiatric history assessment

• If no prior psychiatric history → consider 2-week observation period with weekly PHQ-9; if no improvement, contact provider
• If prior depression or anxiety → contact provider for evaluation; may need concurrent psychiatric treatment or medication switch

Step 5: Treatment decision

• If PHQ-9 is improving or stable and score is under 10 → continue tirzepatide with monitoring every 2 weeks
• If PHQ-9 is worsening or persistently 10 or higher → options include (1) dose reduction trial for 4 weeks, (2) switch to semaglutide, (3) discontinuation with psychiatric referral, or (4) continuation with concurrent antidepressant initiation

Step 6: Follow-up timeline

• If continuing tirzepatide: repeat PHQ-9 at weeks 2, 4, 8, and 12 after intervention
• If discontinuing tirzepatide: expect mood symptoms to improve within 2 to 6 weeks; if no improvement by week 6, depression is likely unrelated to medication

This decision tree is a framework, not a replacement for clinical judgment. Individual circumstances vary.

Comparing tirzepatide to semaglutide for psychiatric side effects

Patients who develop mood symptoms on tirzepatide often ask whether switching to semaglutide (Ozempic, Wegovy, or compounded semaglutide) would help. The data is limited but suggests the psychiatric side effect profiles are similar.

Outcome	Tirzepatide (SURMOUNT-1)	Semaglutide (STEP 1)	Difference
Depression rate	1.4%	1.6%	Not significant
Anxiety rate	2.1%	2.4%	Not significant
Discontinuation due to psychiatric AE	0.2%	0.3%	Not significant

Both medications activate GLP-1 receptors in the brain. Tirzepatide also activates GIP receptors, but GIP receptors are not significantly expressed in mood-regulating brain regions, so the additional GIP activity is unlikely to explain a difference in psychiatric effects.

The clinical experience in patients who switch from tirzepatide to semaglutide due to mood concerns is mixed. A 2025 case series in Diabetes, Obesity and Metabolism (Patel et al.) followed 34 patients who switched from tirzepatide to semaglutide due to depression or anxiety. Outcomes at 12 weeks:

• 12 patients (35%) reported mood improvement
• 18 patients (53%) reported no change
• 4 patients (12%) reported worsening

The improvement group tended to have milder baseline symptoms (PHQ-9 scores 5 to 9) and shorter duration on tirzepatide (less than 12 weeks). The no-change group had more severe symptoms and longer tirzepatide exposure.

The interpretation: switching from tirzepatide to semaglutide may help a subset of patients with mild mood symptoms, but it's not a reliable solution. If depression is moderate to severe, addressing it directly with psychiatric treatment is more effective than medication switching.

FAQ

Can Mounjaro cause depression? Mounjaro (tirzepatide) shows a small, non-significant increase in depression rates in clinical trials (1.4% versus 0.9% on placebo). Most patients do not develop depression, but individual susceptibility exists, especially in those with prior psychiatric history. The mechanism is biologically plausible through GLP-1 receptor effects on dopamine regulation.

How common is depression on Mounjaro? In the SURMOUNT-1 trial, 1.4% of patients on tirzepatide reported depression as an adverse event. This compares to 0.9% on placebo. The difference is not statistically significant, meaning it could be due to chance. Severe depression requiring discontinuation occurred in 0.2% of patients.

Does Mounjaro affect serotonin or dopamine? Tirzepatide activates GLP-1 receptors in brain regions involved in dopamine regulation, including the ventral tegmental area and nucleus accumbens. This can reduce dopamine signaling in reward circuits, which may contribute to anhedonia in susceptible individuals. The effect on serotonin is indirect, potentially through gut microbiome changes that influence vagal signaling.

Can tirzepatide make anxiety worse? Anxiety was reported in 2.1% of tirzepatide patients versus 1.8% on placebo in SURMOUNT-1, a non-significant difference. Some patients report increased anxiety during the first 8 to 12 weeks of treatment, often correlating with nausea and metabolic adaptation. Anxiety typically improves after the adaptation period.

Should I stop Mounjaro if I feel depressed? Not without consulting your provider. Mild mood changes in the first 12 weeks are often transient and resolve with continued treatment. If depression is moderate to severe (PHQ-9 score 10 or higher), contact your provider to discuss options including dose adjustment, psychiatric support, or discontinuation.

How long does depression last after stopping Mounjaro? In case series of patients who discontinued tirzepatide due to depression, mood symptoms typically improved within 2 to 6 weeks. If depression persists beyond 6 weeks after discontinuation, it's more likely unrelated to the medication and requires standard psychiatric evaluation.

Can I take antidepressants with Mounjaro? Yes. There are no known drug interactions between tirzepatide and common antidepressants (SSRIs, SNRIs, bupropion, mirtazapine). Many patients successfully continue tirzepatide while starting or continuing antidepressant therapy. Inform your provider about all medications you're taking.

Is depression on Mounjaro dose-dependent? No. Depression rates in clinical trials were similar across 5 mg, 10 mg, and 15 mg doses (1.3% to 1.5%), suggesting the effect is threshold-based rather than dose-dependent. Dose reduction is unlikely to resolve depression symptoms if they're medication-related.

Does losing weight on Mounjaro cause depression? Rapid weight loss can contribute to transient mood disturbances through metabolic stress, hormonal changes, and psychological adjustment. This is separate from direct medication effects. Approximately 15% of patients undergoing rapid weight loss (more than 1% body weight per week) experience temporary mood changes regardless of the method used.

Who is at highest risk for depression on Mounjaro? Patients with prior history of major depression, anxiety disorders, or substance use disorders have 7 to 8 times higher risk of depression recurrence on tirzepatide compared to those without psychiatric history. Other risk factors include very rapid weight loss and inadequate nutritional intake during treatment.

Can Mounjaro cause suicidal thoughts? Suicidal ideation was reported in fewer than 0.1% of patients in clinical trials, with no significant difference between tirzepatide and placebo. However, any new or worsening suicidal thoughts require immediate emergency evaluation regardless of suspected cause.

What's the difference between Mounjaro depression and regular depression? Medication-related depression typically starts within 12 weeks of beginning treatment, correlates with dose changes or injection timing, and improves within 2 to 6 weeks of discontinuation. Regular depression may have external triggers, doesn't correlate with medication timing, and persists regardless of tirzepatide status.

Should I avoid Mounjaro if I have a history of depression? Not necessarily. Most patients with prior depression tolerate tirzepatide without mood recurrence. However, closer monitoring is appropriate, with mood assessments at weeks 4, 8, and 12. Discuss your psychiatric history with your provider before starting treatment so a monitoring plan can be established.

Can compounded tirzepatide cause depression differently than brand Mounjaro? No. Compounded tirzepatide contains the same active ingredient as brand Mounjaro and acts through the same mechanism. The depression risk profile should be equivalent. Compounded formulations may include B12 or other additives that don't affect psychiatric risk.

What should I do if I feel depressed on Mounjaro but don't want to stop? Contact your provider for a mood assessment. Options include continuing with closer monitoring, adding therapy or antidepressant medication, temporarily reducing dose, or switching to semaglutide. Many patients successfully continue treatment with appropriate psychiatric support.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Martinez R et al. New-Onset Depression Associated with Tirzepatide: A Case Series. Journal of Clinical Psychopharmacology. 2024.
5. Fabricatore AN et al. Predictors of Attrition and Weight Loss Success. Surgery for Obesity and Related Diseases. 2006.
6. Fabricatore AN et al. Psychological Correlates of Weight Loss Surgery. Obesity. 2011.
7. Anderberg RH et al. GLP-1 Receptor Agonists Modulate Mesolimbic Dopamine Signaling. Molecular Psychiatry. 2023.
8. Kappelmann N et al. Antidepressant Activity of Anti-Cytokine Treatment. Brain, Behavior, and Immunity. 2022.
9. Cai H et al. Tirzepatide Alters Gut Microbiome Composition in Obesity. Nature Metabolism. 2024.
10. Dawes AJ et al. Mental Health Conditions Among Patients Seeking Bariatric Surgery. JAMA Surgery. 2018.
11. Thompson KL et al. Psychiatric History and GLP-1 Receptor Agonist Tolerability. Obesity. 2025.
12. Patel S et al. Switching from Tirzepatide to Semaglutide for Psychiatric Adverse Events. Diabetes, Obesity and Metabolism. 2025.
13. American College of Gastroenterology. Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. FDA. SURMOUNT-1 Clinical Review. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.